Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Assets (2022 - 2025)

Mangoceuticals' Assets history spans 4 years, with the latest figure at $16.1 million for Q4 2025.

  • On a quarterly basis, Assets rose 4.68% to $16.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $16.1 million, a 4.68% increase, with the full-year FY2025 number at $16.1 million, up 4.68% from a year prior.
  • Assets hit $16.1 million in Q4 2025 for Mangoceuticals, down from $16.5 million in the prior quarter.
  • Over the last five years, Assets for MGRX hit a ceiling of $21.8 million in Q1 2025 and a floor of $301447.0 in Q1 2024.
  • Historically, Assets has averaged $10.2 million across 4 years, with a median of $14.8 million in 2024.
  • Biggest five-year swings in Assets: plummeted 92.67% in 2024 and later soared 7116.48% in 2025.
  • Tracing MGRX's Assets over 4 years: stood at $1.0 million in 2022, then grew by 4.74% to $1.1 million in 2023, then skyrocketed by 1362.75% to $15.4 million in 2024, then rose by 4.68% to $16.1 million in 2025.
  • Business Quant data shows Assets for MGRX at $16.1 million in Q4 2025, $16.5 million in Q3 2025, and $20.8 million in Q2 2025.